nihonkohden

Press ReleasesNews Release

Nihon Kohden establishes a new hematology analyzer reagent factory in India

May 06, 2022

Nihon Kohden Corporation announced today that Nihon Kohden India, one of its subsidiaries, will establish a new hematology analyzer reagent factory.

1. Purpose
Nihon Kohden established a joint venture to manufacture and supply hematology reagents in 2008 with the aim of strengthening its business structure through stable supply of locally produced reagents, and acquired a 100% ownership of that joint venture in 2015. Nihon Kohden also established Nihon Kohden India in 2011 to enhance its sales and services in India, and Nihon Kohden India absorbed the subsidiary that was engaged in the manufacturing and supply of hematology reagents in 2017. Following the merger, the Nihon Kohden Group has continued to expand and develop the unified hematology instrument and reagent business.
As the install base of hematology instruments is expanding and demand for reagents is also increasing, Nihon Kohden will establish a new hematology analyzer reagent factory to increase its production capacity.
Nihon Kohden’s three-year business plan, BEACON 2030 Phase I, calls for the Company to expand sales to new customer base and promote solution proposals in emerging markets. Nihon Kohden aims at further expanding its international business by providing high quality advanced medical devices and enhancing its recurring business such as consumables and services as well as strengthening its local business structures.

2. Outline of reagent factory in India
Address Haryana, India
Ground area approx. 16,135m2
Floor area approx. 8,900m2 (approx. four times the current plant)
Start of operation Spring 2024 (planned)
Total investment approx. 1.1 billion yen (land acquisition, building construction, production facilities)
Employees 30 (planned)















3.
 Effect on operating results of Nihon Kohden
The effect of establishment of the new factory on the consolidated results for the fiscal year ending March 31, 2023 will be minor.